Comparative Pharmacology
Head-to-head clinical analysis: SULF 15 versus SULFAIR 15.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULF 15 versus SULFAIR 15.
SULF-15 vs SULFAIR-15
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SULF-15 is a sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels (K_ATP), leading to cell membrane depolarization, calcium influx, and exocytosis of insulin.
Sulfadoxine is a long-acting sulfonamide that inhibits dihydropteroate synthase, blocking folate synthesis. Pyrimethamine inhibits dihydrofolate reductase, synergistically inhibiting nucleic acid synthesis in Plasmodium species.
150 mg orally twice daily for 14 days.
15 mg orally every 6 hours, not to exceed 60 mg/day.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to >30 hours in severe renal impairment (CrCl <30 mL/min).
12–15 hours in healthy adults; prolonged to 20–30 hours in moderate hepatic impairment.
Renal excretion accounts for 60-70% of elimination as unchanged drug; biliary/fecal excretion accounts for 20-30% as metabolites and parent compound.
Renal excretion unchanged: 70%; hepatic metabolism to inactive metabolites: 20%; fecal excretion: 10%.
Category C
Category C
Antibiotic (Sulfonamide)
Antibiotic (Sulfonamide)